Mablink Bioscience is a french-based biopharmaceutical company which has developed PSARlink, an innovative and patented hydrophilic drug-linker technology that brings dramatically improved pharmacological properties to antibody-drug conjugates.

Mablink.com
Entrepreneurs

Jean-Guillaume Lafay
Warren Viricel

Related articles

Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners

The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs). Its proprietary ADC technology opens the door for new and better treatment options for cancer patients.

2022.10.14 / 2min read.

Mablink Bioscience, the next generation ADC company, raises €4 Million from a syndicate of private investors led by Elaia.

Mablink Bioscience to move forward its ADC pipeline targeted at cancers with high unmet medical needs.

2021.04.27 / 2min read.

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.